PRWeb The Leader Press Release Distribution
See How PRWeb Works

We're here to help 1-866-640-6397

Login Create Free Account


All Press Releases for December 4, 2006 Subscribe to this News Feed    
 

Weekly Monitor Drug and Diagnostic Development in Neurodegenerative Diseases

HiTIS - life science & biotech intelligence, a European life sciences industry focused competitive intelligence firm, recently launched Neurodegenerative Diseases Therapeutics & Diagnostics Competitive Intelligence Weekly

Paris, France (PRWEB) December 4, 2006 -- HiTIS - life science & biotech intelligence, a European life sciences industry focused competitive intelligence firm, added recently a neurodegenerative diseases therapies-focused publication to its growing family of periodical competitive intelligence reports.

Neurodegenerative Diseases Therapeutics & Diagnostics Competitive Intelligence is a weekly publication reporting industry and academy news in a digital format. The reports cover the whole life cycle of drugs and diagnostics addressing those diseases, from lab-bench to patients, via regulatory authorities.

Drugs and diagnostics (existing and candidates) which are monitored address most frequent neurodegenerative diseases (Alzheimer, Parkinson, Multiple Sclerosis, Huntington, Amyotrophic Lateral Sclerosis) as well as rare disorders (eg. Batten, Menkes, Pick, Sandhoff, Adrenomyeloneuropathy etc.).

"What we are looking for with these publications is to provide pharma, biopharma, biotech and diagnostics industry decision-makers with a unique, synthetic and global source of competitive intelligence data. Time is money, and costs associated with the collection of this information can be tremendous", said Christian Girard.

He added "Our news center daily collects, filters, sorts and saves industry and academy primary information, avoiding press redundancy and delays. The publications are derived products. Each report is divided into several parts, following the homepage introducing mentioned companies and institutions: All News, Regulatory, Research, Preclinical, Clinical, Products, Funding, Financial, Deals, Litigation and IP. Links to companies' websites and full-text releases are included".

A recent issue of this publication can be viewed at:

http://www.txpreview.com/NCI%20Weekly%20-%20%20Y2006%20W43.htm (click to view or copy/paste the link to your browser)

About HiTIS Competitive Intelligence Publications

HiTIS Competitive Intelligence Publications family includes several focused electronic publications covering therapeutic fields or technologies, like:

Vaccines Competitive Intelligence Weekly,
Neurodegenerative Diseases Tx/Dx Competitive Intelligence Weekly, and
Eye Therapies Competitive Intelligence Weekly

Other similar publications will be announced in due time. Note that specific, customized publications may be developed upon request.

About HiTIS - life science & biotech intelligence

HiTIS - life science & biotech intelligence is a European competitive intelligence firm offering various intelligence resources and tools: a web-based competitive intelligence platform, customized R&D Pipelines, and a series of periodical competitive intelligence publications.

A free of charge 7-day news center trial and reports samples are available on request: see www.txpreview.com for more information

Contact

Christian Girard
Founding Partner & Editor
Mobile +33 (0)6 67 26 60 92
Office +33 (0)1 47 88 23 48
www.biotech-intelligence.com and www.txpreview.com
HiTIS - life science & biotech intelligence
11, rue Madiraa - 92400 Courbevoie - France

###

OPTIONS
Printer Friendly Version
Download PDF Version
Download Reader Version
Email this story to a colleague
CONTACT INFORMATION
Christian Girard
HiTIS - life science & biotech intelligence
+33 667 266 092
Email us Here
ATTACHED FILES

There are no multimedia files attached to this release. If this is your release, you may add images or other multimedia files through your PRWeb News Management Console.

ABOUT PRESS RELEASES
If you have any questions regarding information in these press releases please contact the company listed in the press release. Please do not contact PRWeb. We will be unable to assist you with your inquiry. PRWeb disclaims any content contained in these release. Our complete disclaimer appears here.